title: BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci.
abstract: Staphylococci are a major cause of infections associated with indwelling medical devices. Biofilm formation on these devices adds to the antibiotic resistance seen among clinical isolates. RNAIII-inhibiting peptide (RIP) is a heptapeptide that inhibits staphylococcal pathogenesis, including biofilm formation, by obstructing quorum sensing mechanisms. Bismuth ethanedithiol (BisEDT) also prevents biofilm formation at subinhibitory concentrations. RIP and BisEDT were combined to prevent infections in a rat graft model, using antibiotic sensitive and resistant strains of Staphylococcus aureus and Staphylococcus epidermidis. BisEDT, RIP, or rifampin, or their combinations reduced the graft associated bacterial load over seven days. BisEDT-RIP was the best combination, reducing bacterial load to undetectable levels. BisEDT-RIP may prove useful for coating medical devices to prevent staphylococcal infections.
authors.affiliation: Cardio Pulmonary Research Institute, Winthrop-University Hospital, SUNY Stony Brook School of Medicine, Mineola 11501, New York, NY, USA. pdomenico@winthrop.org
authors.forename: Philip
authors.initials: P
authors.lastname: Domenico
authors.forename: Ellen
authors.initials: E
authors.lastname: Gurzenda
authors.forename: Andrea
authors.initials: A
authors.lastname: Giacometti
authors.forename: Oscar
authors.initials: O
authors.lastname: Cirioni
authors.forename: Roberto
authors.initials: R
authors.lastname: Ghiselli
authors.forename: Fiorenza
authors.initials: F
authors.lastname: Orlando
authors.forename: Moshe
authors.initials: M
authors.lastname: Korem
authors.forename: Vittorio
authors.initials: V
authors.lastname: Saba
authors.forename: Giorgio
authors.initials: G
authors.lastname: Scalise
authors.forename: Naomi
authors.initials: N
authors.lastname: Balaban
mesh_terms: D000818:Animals; D018441:Biofilms / Q000187:drug effects*; D024881:Drug Resistance, Bacterial; D004357:Drug Synergism; D020007:Implants, Experimental / Q000009:adverse effects*; D008297:Male; D008623:Mercaptoethanol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008954:Models, Biological; D009842:Oligopeptides / Q000627:therapeutic use*; D011093:Polyethylene Terephthalates; D051381:Rats; D017208:Rats, Wistar; D012293:Rifampin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects
chemical_list: D009842:Oligopeptides; D011093:Polyethylene Terephthalates; C111711:RNAIII inhibiting peptide; D008623:Mercaptoethanol; C031854:1,2-ethanedithiol; D012293:Rifampin